The smoking cessation drug AXS-05 reaches its main endpoint in the course of smoking cessation

tobacco dependence is a chronic, highly recurrent diseaseThe World Health Organization has included tobacco dependence as a disease in the International Classification of Diseases, recognizing that tobacco dependence is one of the greatest threats to theof thehealth(http:// of human beingsThere are more than 40 million smokers in the United States, and more than 430,000 people die each year from smoking-related conditions, one in five deaths caused by smokingSmoking is often a manifestation of nicotine addiction that goes beyond habittoday, clinical stage bio
medicine(http://, which focuses on developing new treatments for central nervous system diseases,http://
announced today that it has reached its main endpoint in the course of smoking cessation in itsaxsome-05the(http:// of the smoking cessationdrug, and the treatment of amphetaminesAXS-05 significantly reduces the number of daily smokersAs a non-nicotine smoking cessation drug, AXS-05 is an innovative oral NMDA receptor antagonistIt is made up of dextromethorphan and amphetamines and uses Axsome's metabolic suppression techniquesright meschafin is a non-competitive NMDA receptor antagonist, it is also an inhibitor of sigma-1 receptor agonists, niacin-type acetylcholine receptor antagonists, and 5-serotonin and norepinephrine transportproteinsamphetamines improve the bioavailability of right meschafin, but also dosage norepinephrine and dopamine reuptake inhibitors, and niacin-type acetylcholine receptor antagonistsas an innovative treatment for severe depression (MDD), AXS-05 has been recognized as a breakthrough therapy awarded by theFDA(http://In addition, potential indications of AXS-05 include inflammatory symptoms in patients with Alzheimer's disease (AD) and refractory depression (TRD)During a three-week smoking cessation session at Duke University's Smoking Cessation Center, the AXS-05 group (which smoked an average of 8.49 cigarettes per day) reduced the daily smoking rate by an additional 25 percent compared to the amphetamine group (an average of 6.79 cigarettes per day)